Browsing by Author "Balık Aydın, Berrin"
Now showing items 1-12 of 12
-
Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort
Mutlu, Yaşa Gül; Güvenç, Birol; Serin, İstemi; Balık Aydın, Berrin; Alacacıoğlu, İnci; Güven, Serkan; Sevindik, Ömür Gökmen (American Society of Hematology, 2022)Treatment free remission (TFR) is one of the main goals of therapy in Chronic Myeloid Leukemia (CML). Patient perspective and expectations have an indicative effect on discontinuation decisions. We analyzed 116 CML patients' ... -
CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: A multicenter study
Demirci, Ufuk; Kırkızlar, Hakkı Onur; Ümit, Elif Gülsüm; Gürsoy, Vildan; Pınar, İbrahim Ethem; Özkalemkaş, Fahir; Güven, Zeynep Tuğba; Kaynar, Leylagül; Keklik Karadağ, Fatma; Saydam, Güray; Ekinci, Ömer; Merter, Mustafa; Aras, Merih Reis; Albayrak, Murat; Karaman Gülsaran, Sedanur; Baş, Volkan; Balık Aydın, Berrin; Beköz, Hüseyin Saffet; Can, Ferda; Dilek, İmdat; Mehtap, Özgür; Öztürk, Erman; Çobanoğlu Şimşek, Bengü; Yıldırım, Murat; Aylı, Meltem; Ataş, Ünal; Salim, Ozan; Ayer, Mesut; Birtaş Ateşoğlu, Elif; Akay, Olga Meltem; Kurt Yüksel, Meltem; Paydaş, Semra; Korkmaz, Selçuk; Öz Puyan, Fulya; Demir, Ahmet Muzaffer (Springer Science and Business Media Deutschland GmbH, 2022)Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and comprises a heterogeneous group of disease. While classification of B-cell lymphomas has been evolving to include clonality ... -
Clinical characteristics and outcomes of COVID-19 in Turkish patients with hematological malignancies
Civriz Bozdağ, Sinem; Cengiz Seval, Güldane; Yönal Hindilerden, İpek; Hindilerden, Fehmi; Andıç, Neslihan; Baydar, Mustafa; Aydın Kanyar, Lale; Toprak, Selami Koçak; Göksoy, Hasan Sami; Balık Aydın, Berrin; Demirci, Ufuk; Can, Ferda; Özkocaman, Vildan; Gündüz, Eren; Güven, Zeynep Tuğba; Özkurt, Zübeyde Nur; Demircioğlu, Sinan; Beksaç, Meral; İnce, İdris; Yılmaz, Umut; Eroğlu Küçükdiler, Hilal; Abishov, Elgün; Yavuz, Boran; Ataş, Ünal; Mutlu, Yaşa Gül; Baş, Volkan; Özkalemkaş, Fahir; Üsküdar Teke, Hava; Gürsoy, Vildan; Çelik, Serhat; Çiftçiler, Rafiye; Yağcı, Münci; Topçuoğlu, Pervin; Çeneli, Özcan; Abbasov, Hamza; Selim, Cem; Ar, Muhlis Cem; Yücel, Orhan Kemal; Sadri, Sevil; Albayrak, Canan; Demir, Ahmet Muzaffer; Güler, Nil; Keklik, Muzaffer; Terzi, Hatice; Doğan, Ali; Yegin, Zeynep Arzu; Kurt Yüksel, Meltem; Sadri, Soğol; Yavaşoğlu, İrfan; Beköz, Hüseyin Saffet; Aksu, Tekin; Maral, Senem; Erol, Veysel; Kaynar, Leylagül; İlhan, Osman; Bolaman, Ali Zahit; Sevindik, Ömür Gökmen; Akyay, Arzu; Özcan, Muhit; Gürman, Günhan; Ünal, Şule; Yavuz, Yasemin; Diz Küçükkaya, Reyhan; Özsan, Güner Hayri (NLM (Medline), 2022)Objective: Patients with solid malignancies are more vulnerable to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection than the healthy population. The outcome of SARS-CoV-2 infection in highly ... -
Clinical outcomes and treatment patterns of primary central nervous system lymphoma: Multicenter retrospective analysis
Güven, Serkan; Yavuz, Boran; Erdoğan Yücel, Elçin; Karataş, Aylin Fatma; Özsan, Güner Hayri; Demirkan, Fatih; Ündar, Bülent; Özcan, Mehmet Ali; Kiper, Hatice Demet; Çetintepe, Tuğba; Göçer, Mesut; Kurtoğlu, Erdal; Balık Aydın, Berrin; Sevindik, Ömür Gökmen; Yiğit Kaya, Süreyya; Alacacıoğlu, İnci (Kare Publishing, 2023)Objectives: Primary central nervous system lymphoma (PCNSL) is a rare malignant disease with poor prognosis. Its low incidence leads to challenges in decision-making for treatment. As a matter of fact, there is still no ... -
Comparison of efficacy and safety of generic plerixafor vs original plerixafor in the mobilization of myeloma patients
Sevindik, Ömür Gökmen; Bilgen, Hülya; Serin, İstemi; Melek, Elif; Karakuş, Volkan; Çerçi, Kübra; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Sadri, Sevil; Beköz, Hüseyin Saffet; Kaynar, Leylagül (American Society of Hematology, 2022)Introduction The commonest indication for an Autologous Stem Cell Transplantation (ASCT) is still Multiple Myeloma. A successful mobilization of hematopoietic stem cells (HSC) is a sine qua non of ASCT. The introduction ... -
Evaluation of neurological imaging after hematopoietic stem cell transplantation in adults
Sadri, Sevil; Polat, Burcu; Balık Aydın, Berrin; Koçar, Hakan; Gemici, Aliihsan; Beköz, Hüseyin Saffet; Sevindik, Ömür Gökmen; Sargın, Fatma Deniz (Yüzüncü Yıl University Faculty of Medicine, 2022)To investigate the risk factors for, and the incidence of, structural abnormalities in brain imaging among hematopoetic stem cell transplant (HSCT) patients and to correlate these findings with physical examinations. This ... -
First-line usage of daratumumab, lenalidomide, dexamethasone (DRd) combination in a case of castleman disease variant of polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (CD-POEMS)
Sevindik, Ömür Gökmen; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Serin, İstemi (Lippincot Williams & Wilkins, 2022)Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome (POEMS) is a rare paraneoplastic syndrome of an underlying plasma cell disorder (PCD).1 Castleman disease (CD), itself, can ... -
Mutation profile of the patients diagnosed with myeloid neoplasia tested with next generation sequencing and clinical implications
Mutlu, Yaşa Gül; Balık Aydın, Berrin; Ayaz, Akif; Seca, Fatma; Sevindik, Ömür Gökmen (Inonu University Faculty of Medicine, 2022)Aim: To analyze the distribution of gene mutations in myeloid neoplasias, based on next generating sequencing technology (NGS) and evaluate their clinical implications and impact on the risk stratification. Materials and ... -
Persistent polyclonal B-Cell lymphocytosis with binucleated lymphocytes
Balık Aydın, Berrin; Mutlu, Yaşa Gül; Sevindik, Ömür Gökmen (Galenos Yayıncılık, 2021)A 46-year-old female was admitted to our clinic suffering from long-standing leukocytosis. She was evaluated at another hospital regarding this lymphocytic leukocytosis (absolute lymphocyte count: 10770/µL) with no final ... -
Rituximab-vemurafenib combination for the treatment of relapsed/Refractory hairy cell leukemia
Sevindik, Ömür; Gemici, Aliihsan; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Çakır, Aslı (CIG Media Group, 2020)Objective: The management of R/R-HCL is not standardized yet. Patients with HCL universally harbor BRAF mutations, which makes BRAF inhibitors a potential treatment approach. The effi cacy and safety of the BRAF inhibitor ... -
To rechallenge or not to rechallenge, that is the question? An unsuccessful attempt of hypomethylating agent plus venetoclax in an elderly FLT3-positive relapsed acute myeloid leukemia patient after a yearlong period of remission
Sevindik, Ömür Gökmen; Mergen, Mahmut; Mergen, Sena; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Serin, İstemi (Springer Science and Business Media Deutschland GmbH, 2022)Dear Editor, Acute myeloid leukemia is the most common sub-type of acute leukemia in adulthood [1]. It has a detrimental prognosis with conventional combination chemotherapy, mainly with anthracyclines and cytarabine. ...
